Big pharma says drug prices reflect R&D cost. Researchers call BS

At the end of September, a spot of good news: Relyvrio, a new drug for treating amyotrophic lateral sclerosis-or ALS, a neurological disorder without a cure-was approved in the United States.

Read at Ars Technica